Sign In
Buy RGEN
$121.73
+0.600 (+0.495%)
At Close: Jun 03, 2026
Repligen (RGEN) Q2 Earnings Meet Estimates
09:46am, Tuesday, 30'th Jul 2024
Repligen (RGEN) came out with quarterly earnings of $0.33 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.53 per share a year ago.
Repligen Reports Second Quarter 2024 Financial Results
07:30am, Tuesday, 30'th Jul 2024
WALTHAM, Mass., July 30, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its s
Repligen Announces Agreement to Acquire Chromatography Innovator Tantti
04:00pm, Monday, 29'th Jul 2024
WALTHAM, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into a
Analysts Estimate Repligen (RGEN) to Report a Decline in Earnings: What to Look Out for
11:06am, Tuesday, 23'rd Jul 2024
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen to Report Second Quarter 2024 Financial Results
07:30am, Tuesday, 16'th Jul 2024
Webcast and Conference Call to Be Held Tuesday, July 30, 2024, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, July 30, 2024, at 8:30 a.m. ET
Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?
08:35am, Monday, 24'th Jun 2024
Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Top 3 Health Care Stocks That Could Blast Off In June
08:22am, Friday, 21'st Jun 2024
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Repligen (RGEN) Promotes CCO, Shares Fall on Leadership Change
12:45pm, Friday, 14'th Jun 2024
Repligen (RGEN) appoints Olivier Loeillot as the company's new president and chief executive officer, effective from Sep 1, 2024. Stock falls on the news.
Repligen Announces CEO Transition Plan
07:00am, Thursday, 13'th Jun 2024
Tony J. Hunt to Transition from Chief Executive Officer to Executive Chair, Olivier Loeillot Appointed to Role of President and Chief Executive Officer, Effective September 1, 2024 Tony J. Hunt to Tra
ST. PAUL, Minn. & WALTHAM, Mass.--(BUSINESS WIRE)--Ecolab today announced that its Purolite resin business, together with Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioproc
Repligen Corporation to Present at Upcoming June Investor Conferences
07:30am, Wednesday, 22'nd May 2024
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting
Repligen Corporation to Present at Upcoming May Investor Conferences
07:30am, Tuesday, 07'th May 2024
WALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participati
Repligen (RGEN) Q1 Earnings Miss, Revenues Beat Estimates
12:26pm, Thursday, 02'nd May 2024
Repligen's (RGEN) first-quarter 2024 earnings miss estimates while revenues beat the same.
Repligen (RGEN) Misses Q1 Earnings Estimates
09:51am, Wednesday, 01'st May 2024
Repligen (RGEN) came out with quarterly earnings of $0.28 per share, missing the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.64 per share a year ago.
Repligen Reports First Quarter 2024 Financial Results
07:30am, Wednesday, 01'st May 2024
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fi
